ArticleScientific reports2025
The prognostic value of secreted frizzled-related protein 2 in elderly patients with heart failure: a single-center retrospective study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exosome-basedRegenerative biomaterials · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study was conducted to assess the prognostic value of secreted frizzled-related protein 2 (SFRP2) for mortality and readmission in elderly patients with acute exacerbation of chronic heart failure (HF). Elderly patients hospitalized for worsening chronic HF were enrolled in the present study. We detected the concentration of serum SFRP2 in these patients. The primary endpoint of this study was defined as all-cause mortality and the secondary endpoint was a composite of all-cause mortality and readmission due to HF, acute myocardial infarction, and malignant arrhythmia during a median follow-up period of 450 (interquartile range 224-942) days. Multivariable Cox proportional hazard models were performed to evaluate the prognostic value of SFRP2. Of 161 patients at baseline, we observed 72 events (25 deaths and 47 readmissions). Serum SFRP2 levels were significantly elevated in elderly HF patients with events relative to those without and control subjects (all P < 0.001). The Kaplan-Meier analysis showed a significantly increased risk of all-cause mortality and cardiovascular readmissions stratified by the optimal cut-off value of serum SFRP2 level (log-rank P < 0.005). An elevated SFRP2 level and N-terminal pro-B-type natriuretic peptide (NT-proBNP) level was independently and significantly associated with the primary endpoint and secondary endpoint (adjusted hazard ratio [HR] 2.334, 95% confidence interval [CI] 1.059-5.147;P = 0.036 and HR 2.326, 95% CI 1.426-3.794;P = 0.001, respectively) in multivariable Cox regression analysis. A higher level of serum SFRP2 can be considered as an independent predictor of poorer clinical outcomes for elderly patients with acute exacerbation of chronic heart failure, indicating that evaluation of SFRP2 could provide more useful information for the long-term prognosis in these patients beyond NT-proBNP.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.